Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Harnessing gd T Cell Metabolism to Optimize Use in Cancer Immunotherapy

FY 2022-23

Summary
Cancer immunotherapy is an emerging and promising form of treatment for cancer, especially in light of the limited efficacy and high toxicity of traditional treatments like chemotherapy and radiation. This form of treatment involves the modification of a patient's own immune cells to target tumours. Cytotoxic alpha-beta T cells and natural killer (NK) cells are immune cells that are most often used in this therapy, but gamma-delta T cells are emerging players in the field. Gamma-delta T cells are a unique subset of T cells that have properties of both conventional alpha-beta T cells and NK cells. They show promise for use in cancer immunotherapy because of their cancer-targeting functions, as well as their unique ability to target tumours that try to evade the immune system by using alternative pathways to recognize these tumours. Despite this potential, like other immune cells, solid tumours are able to suppress their activation, preventing their therapeutic use against many cancers. Recent research with NK cells shows the potential of modulating metabolic pathways to prevent this immunosuppression. In gamma-delta T cells, certain energy sensors and gene expression inducers increase the activity of metabolic pathways that are important for their activation and cytotoxic activity. Hence, I present the potential of targeting this particular metabolic pathway to improve the efficacy of gamma-delta T cells against solid tumours in cancer immunotherapy.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
485938
Name
Mehboob Misaal
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Harnessing gd T Cell Metabolism to Optimize Use in Cancer Immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
?D T Cells; Anti-Tumour Efficacy; Cancer Immunotherapy; Hif1a; Immunometabolism; Immunosuppression; Mtor Activity; Nk Cells; Promoting Glycolysis; Tumour Microenvironment
Abstract
Cancer immunotherapy is an emerging and promising form of treatment for cancer, especially in light of the limited efficacy and high toxicity of traditional treatments like chemotherapy and radiation. This form of treatment involves the modification of a patient's own immune cells to target tumours. Cytotoxic alpha-beta T cells and natural killer (NK) cells are immune cells that are most often used in this therapy, but gamma-delta T cells are emerging players in the field. Gamma-delta T cells are a unique subset of T cells that have properties of both conventional alpha-beta T cells and NK cells. They show promise for use in cancer immunotherapy because of their cancer-targeting functions, as well as their unique ability to target tumours that try to evade the immune system by using alternative pathways to recognize these tumours. Despite this potential, like other immune cells, solid tumours are able to suppress their activation, preventing their therapeutic use against many cancers. Recent research with NK cells shows the potential of modulating metabolic pathways to prevent this immunosuppression. In gamma-delta T cells, certain energy sensors and gene expression inducers increase the activity of metabolic pathways that are important for their activation and cytotoxic activity. Hence, I present the potential of targeting this particular metabolic pathway to improve the efficacy of gamma-delta T cells against solid tumours in cancer immunotherapy.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mehboob, Misaal
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~